Does excessive body mass affect the rhGH therapy outcomes in GHD children?

Tomasz Maroszczuk; Jan Maciej Kapała; Aleksandra Sitarz; Anna Kącka-Stańczak; Dorota Charemska

doi:10.5114/pedm.2024.142590

eISSN: 2083-8441
ISSN: 2081-237X

Pediatric Endocrinology Diabetes and Metabolism

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

Journal integrated with

3/2024
vol. 30

Send email

Copy url:

abstract:

Original paper

Does excessive body mass affect the rhGH therapy outcomes in GHD children?

Tomasz Maroszczuk

¹

,

Jan Maciej Kapała

¹

,

Aleksandra Sitarz

¹

,

Anna Kącka-Stańczak

¹

,

Dorota Charemska

¹

Department of Clinical Paediatrics, Faculty of Medical Sciences, University of Warmia and Mazury, Poland

Pediatr Endocrinol Diabetes Metab 2024; 30 (3): 116-124

DOI: https://doi.org/10.5114/pedm.2024.142590

Online publish date: 2024/10/18

View full text Get citation

PlumX metrics:

Introduction
For 35 years, recombinant human growth hormone (rhGH) has been successfully used worldwide to treat children with short stature related to growth hormone deficiency (GHD). Growth hormone therapy requires an individual approach to the patient due to varying responses to the treatment. Excessive body weight is one of the factors influencing the response.

Aim of the study
To evaluate the impact of excessive body mass on rhGH therapy effectiveness in GHD children.

Material and methods
165 short-statured children with isolated GHD (mean age 10.72 ±3.33 years), treated with rhGH for at least one year (mean follow-up 4.32 ±1.80 years), were separated into 3 groups based on their BMI standard deviation score (SDS). Bone age, height, weight, insulin-like growth factor 1 level, and rhGH dose were obtained up to 10 years with one-year intervals.

Results
The mean change in height SDS in the first year was 0.52 ±0.41 SD and 0.60 ±0.32 SD for normal and excessive body weight children, respectively. The mean height velocity, based on the height SDS measured over the consecutive 5 years, was 0.44±0.25 SD/year for the normal-weight group and 0.32 ±0.24 SD/year for the excessive body weight group (p < 0.1).

Conclusions
Excess body weight has a significant impact on rhGH therapy outcomes. This correlates with the height increase in the first year of observation; however, long-term observation has shown that children diagnosed with overweight or obesity achieve significantly worse results compared to their normal-weight peers.

keywords:

Does excessive body mass affect the rhGH therapy outcomes in GHD children?

Tomasz Maroszczuk 1 , Jan Maciej Kapała 1 , Aleksandra Sitarz 1 , Anna Kącka-Stańczak 1 , Dorota Charemska 1

obesity, body mass index, retrospective cohort study, growth hormone deficiency, recombinant human growth hormone

Tomasz Maroszczuk

¹

,

Jan Maciej Kapała

¹

,

Aleksandra Sitarz

¹

,

Anna Kącka-Stańczak

¹

,

Dorota Charemska

¹